Search

A recent study conducted by researchers at the University of Simon Bolivar has explored the role of the Epstein-Barr virus (EBV) and human endogenous retroviruses (HERV-E) in systemic lupus erythematosus (SLE). The study found a significant association between SLE and EBV, with an increase in EBV gene expression observed in SLE patients. Additionally, the study identified an overexpression of HERV-E and alterations in immune regulatory pathways in SLE patients. These findings suggest that both viral factors and host gene expression may contribute to the pathogenesis of SLE. [Extracted from the article]

A new report from the Affiliated Hospital of Inner Mongolia Medical University in Hohhot, China, presents fresh data on lupus nephritis (LN). The researchers conducted a joint analysis of transcriptomic data from PBMCs and kidney samples to explore molecular biomarkers associated with LN. They identified differentially expressed genes and functional modules related to LN, with the neutrophil activation pathway being highly active in both PBMCs and kidney. The study suggests that targeting neutrophils to modulate their activation levels and inhibit aberrant gene expression could be a potential therapeutic strategy for treating LN. [Extracted from the article]

A recent study conducted by researchers at Thanjavur Medical College in Tamil Nadu, India, explores the topic of neuropsychiatric lupus, a condition where patients with systemic lupus erythematosus (SLE) experience symptoms related to the central nervous system. The study highlights the importance of considering connective tissue disorders as a potential cause of seizures in patients presenting with isolated late-onset seizures. The researchers found that antiphospholipid antibodies and anti-ribosomal P antibodies are frequently associated with neuropsychiatric lupus, increasing the risk of neurological complications. The study focuses on five female patients who exhibited neuropsychiatric symptoms, ultimately attributing the cause to SLE involvement in the central nervous system. [Extracted from the article]

A recent report from Baylor University highlights a case of pediatric-onset systemic lupus erythematosus (pSLE) caused by a rare genetic disorder called p40phox deficiency. The patient, an 18-year-old female, experienced symptoms of pSLE starting at the age of 7, including fever, rash, autoantibody production, and recurrent infections. Genetic analysis revealed biallelic pathogenic variants in NCF4, resulting in p40phox deficiency. This case emphasizes the importance of considering genetic causes in cases of pre-pubertal onset and atypical pSLE. [Extracted from the article]

Researchers from the First Affiliated Hospital of Shenzhen University in China have used machine learning algorithms and Non-negative Matrix Factorization (NMF) to analyze single-cell datasets from kidney biopsies in order to gain a better understanding of lupus nephritis (LN). Through this analysis, they identified various immune cell populations and their roles in LN progression, and constructed 102 machine learning-based immune-related gene (IRG) predictive models. These models demonstrated high predictive accuracy and highlighted six hub IRGs as key diagnostic markers for LN. The study suggests that integrating advanced genomic tools and machine learning algorithms can improve the diagnosis and management of complex autoimmune diseases like LN. [Extracted from the article]

A recent study conducted by researchers from the University of Pittsburgh explores the coexistence of Turner Syndrome and lupus in a female patient. Turner Syndrome is a rare genetic disorder characterized by the absence or partial absence of one X chromosome in females. The study suggests a potential link between the gene-dose effect from the X-chromosome and the development of lupus. The researchers found higher levels of DNA methylation in interferon-regulated genes in the patient, which may provide a protective effect against lupus. This research was supported by the NIH National Institute of Allergy & Infectious Diseases. [Extracted from the article]

A recent study conducted by researchers at the Icahn School of Medicine at Mount Sinai highlights the disparities in access to care and genetic research for individuals with systemic lupus erythematosus (SLE) within the African diaspora. SLE is an autoimmune condition that disproportionately affects non-White ethnic and racial groups, particularly those in the African diaspora. The study emphasizes the limited understanding of genetic risk factors in African ancestry populations due to social and environmental influences on research participation, disease presentation, and healthcare access. The researchers also identify opportunities to address these disparities and promote scientific equity for individuals affected by SLE within the global African diaspora. [Extracted from the article]

A recent study conducted at the Second Affiliated Hospital of Kunming Medical University in China explored the role of JunD, a protein, in the regulation of B cell function in patients with systemic lupus erythematosus (SLE). The researchers found that JunD was upregulated in the B cells of SLE patients, and its overexpression facilitated cellular proliferation and modulation of immune and autophagic status. The study suggests that JunD plays a significant role in the pathogenesis of SLE by regulating B cell function. Further research is needed to fully understand the mechanisms by which JunD functions in SLE. [Extracted from the article]

A recent study conducted at Capital Medical University has reported on a case of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) coexisting with systemic lupus erythematosus (SLE) due to a mutation in the TREX1 gene. RVCL-S is a rare autosomal dominant systemic microvascular disorder often prone to misdiagnosis. The study highlights the importance of conducting systemic immunity screening in patients with RVCL-S to prevent potential diagnostic oversights. Treatment with immunosuppressive therapy led to improvements in communication and mobility for the patient. Further research is needed to develop better diagnostic and treatment approaches for RVCL-S. [Extracted from the article]

A recent study conducted by researchers at Sofia University "St. Kliment Ohridski" explores the correlation between phospholipase A2 (PLA2) enzyme activity and anti-complement antibodies in patients with systemic lupus erythematosus (SLE). SLE is an autoimmune disease that affects multiple organs or organ systems and is characterized by chronic inflammation. The study aimed to evaluate PLA2 activity and identify the dominant type of PLA2 enzymes in a cohort of Bulgarian patients with SLE and lupus nephritis (LN). Additionally, the researchers investigated whether increased PLA2 activity was correlated with the presence of autoantibodies specific to complement proteins C3 and factor H. [Extracted from the article]

A recent report from Boston Children's Hospital presents new findings on lupus, an autoimmune disease. The research focused on identifying non-coding variants in the genome that contribute to the risk of systemic lupus erythematosus (SLE). By analyzing single-nucleotide polymorphisms (SNPs) from SLE risk loci, the researchers identified a set of functional non-coding lupus risk variants. They also discovered a regulatory pathway involving a specific SNP, a transcription factor called Ikaros, and a regulator called IKKe, which are implicated in the risk for SLE. This research provides valuable insights into the genetic factors underlying lupus and may contribute to future prevention and treatment strategies. [Extracted from the article]

A case report from the Department of Dermatology in Karachi, Pakistan, discusses the uncommon presentation of Juvenile Systemic Lupus Erythematosus (JSLE) in an 8-year-old boy who was previously diagnosed with atopic eczema. JSLE is a complex autoimmune disease that typically affects girls and is associated with increased mortality and morbidity. The case study highlights the early development of stroke within one year of the JSLE diagnosis. This research provides valuable insights into the underlying genetics and immune responses associated with JSLE. [Extracted from the article]

A recent study conducted by researchers at the University of Guadalajara in Mexico explored the association between interleukin 21 (IL-21) levels and systemic lupus erythematosus (SLE), an autoimmune disease. The study found that patients with SLE had higher levels of IL-21 compared to healthy controls. Additionally, the levels of IL-21 remained elevated even when patients were in remission. The researchers suggest that IL-21 could serve as a potential biomarker for SLE and further longitudinal studies are needed to understand its relationship with the clinical phenotypes of the disease. [Extracted from the article]

A recent report discusses the connection between systemic lupus erythematosus (SLE) and strokes. Individuals with SLE are at an increased risk of cerebrovascular events, particularly strokes, which can present with a diverse range of symptoms. This makes it challenging to identify optimal management plans and select medications for individual patients. The review aims to explore the pathological connection between SLE and strokes, examining neurological manifestations, risk factors, prevention strategies, management plans, and available research tools. The goal is to improve patient outcomes by optimizing management strategies and discovering new medications tailored to SLE patients at risk of stroke. [Extracted from the article]

A new report from Harvard University T.H. Chan School of Public Health explores the relationship between ultraprocessed food (UPF) intake and the incidence of systemic lupus erythematosus (SLE) among women. The study, conducted using data from the Nurses' Health Study cohorts, found that higher cumulative average daily UPF intake was associated with a more than 50% increased risk of SLE and a doubled risk for anti-double-stranded DNA (dsDNA) antibody in patients with SLE. The researchers suggest that these findings may be due to the deleterious effects of UPF on systemic inflammation and immunity. [Extracted from the article]

A recent study conducted at Yale University has shed light on the role of DNASE1L3 deficiency in systemic lupus erythematosus (SLE), an autoimmune disease. The researchers engineered a long-acting enzyme biologic with dual DNASE1/DNASE1L3 activity that prevented the development of lupus in mice and rescued animals from death in induced lupus models. The biologic was also found to efficiently degrade DNA in SLE plasma. These findings suggest that a replacement DNASE tailored to bypass pathogenic mechanisms restricting DNASE1L3 activity could be an effective treatment for SLE and other autoimmune diseases characterized by aberrant DNA accumulation. [Extracted from the article]

A recent study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, explores the immunology of systemic lupus erythematosus (SLE), a challenging autoimmune disease. The research examines the complex factors that contribute to SLE, including genetics, environment, sex, and immunoregulatory factors. The study also discusses potential treatment strategies and the potential for precision medicine in SLE care. The research has been peer-reviewed and published in Nature Immunology. For more information, readers can contact George C. Tsokos at Harvard Medical School, Beth Israel Deaconess Medical Center. [Extracted from the article]

Researchers from the Universidad Cooperativa de Colombia conducted a cross-sectional study to explore the potential associations between high-density lipoprotein (HDL) levels and inflammasome components in the context of systemic lupus erythematosus (SLE). They enrolled 50 patients with SLE and 50 healthy controls and found that HDL levels were lower in the SLE patients, particularly those with active disease. The SLE patients also had higher concentrations of inflammatory cytokines and upregulated gene expression of inflammasome components. The study suggests that HDL is important for SLE beyond its role in atherosclerosis and may be involved in inflammation regulation through inflammasome immunomodulation. [Extracted from the article]

A recent study conducted at Nanjing Drum Tower Hospital in China investigated the potential role of curcumin in treating lupus nephritis (LN), a kidney disease associated with systemic lupus erythematosus. The study found that curcumin effectively reduced inflammation and inhibited the migration of neutrophils, which are immune cells involved in the development of LN. This was achieved by inhibiting the PI3K/AKT/NF-kB signaling pathway. The findings suggest that curcumin may be a promising therapeutic option for LN, providing new targets for treatment. [Extracted from the article]

A recent study conducted at Meyer Children's Hospital in Florence, Italy, has provided new insights into lupus nephritis, a severe complication of systemic lupus erythematosus (SLE). The study focused on early-onset lupus nephritis, which occurs in childhood and is associated with greater disease severity and lower responsiveness to treatment compared to adult-onset lupus nephritis. The researchers also discussed monogenic lupus, a group of conditions caused by single gene variants that often present in childhood and have poor response to standard treatments. This research contributes to a better understanding of lupus nephritis and may inform the management of long-term complications. [Extracted from the article]

New research from Capital Medical University explores the role of mitochondrial dysfunction in the development of systemic lupus erythematosus (SLE). The study focuses on the deletion of the mitochondrial membrane protein Fam210b and its association with SLE. Through the use of Fam210b knockout mice, the researchers found that the absence of Fam210b led to lupus-like symptoms, including skin ulcerations, splenomegaly, and an increase in autoantibodies. The study suggests that Fam210b reduction may serve as a key marker for triggering the development of SLE. [Extracted from the article]

A recent study conducted at Beth Israel Deaconess Medical Center in Boston, Massachusetts, has found that the protein phosphatase 2A (PP2A) regulatory subunit PPP2R2A plays a role in regulating the immune response in lupus-prone mice. The deficiency of PPP2R2A promotes NAD+ biosynthesis, which inhibits the production of proinflammatory cytokines and promotes the differentiation of regulatory T cells. The study suggests that targeting NAD+ biosynthesis could be a potential therapeutic strategy for lupus. This research was supported by the National Institutes of Health (NIH) in the United States. [Extracted from the article]

A recent study conducted by researchers at the Second Hospital of Shanxi Medical University explores the relationship between gut microbiota and T lymphocyte subsets in systemic lupus erythematosus (SLE). The study found that SLE patients had decreased proportions of Tregs, Tfh cells, and Naive CD4 + T cells, while proportions of Th17 cells and gdT cells increased. The diversity of gut microbiota in SLE patients was significantly decreased, and certain species of flora were found to be distinctly different in the SLE group. The study suggests that the changes in gut microbiota and T lymphocyte subsets may disrupt immune balance and contribute to the development of SLE. Further research in this area could provide new insights for the treatment of SLE. [Extracted from the article]

Researchers from Sohag University have conducted a study on lupus nephritis (LN), a severe manifestation of systemic lupus erythematosus (SLE). The study focused on the role of Interleukin 17 (IL-17) in LN and its correlation with disease activity and histopathological classification. The researchers found that LN patients had higher levels of IL-17A compared to non-LN patients. They also discovered that IL-17A was positively correlated with disease activity indices and negatively correlated with certain markers. The study suggests that IL-17A may serve as a prognostic marker for LN in SLE patients. [Extracted from the article]

A recent study conducted by the Department of Orthopedics explored the potential association between rheumatic diseases and bone mineral density (BMD) and fractures. The study used a bidirectional Mendelian analysis and analyzed three rheumatic diseases: ankylosing spondylitis (AS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). The results showed that there was no evidence of a causal effect of AS on BMD or fractures. However, RA was found to have a positive causal relationship with fractures of the femur and forearm, and SLE was linked to fractures of the forearm. Additionally, increasing BMD was associated with a reduced risk of AS. These findings provide insight into the risk factors for fractures and BMD in rheumatic diseases. [Extracted from the article]

A research report from the National University of Lujan in Argentina discusses the findings on systemic lupus erythematosus (SLE), an autoimmune disease. The study focuses on the role of the human microbiome in maintaining the balance between microorganisms and the immune system. The researchers found differences in the composition of the intestinal microbiota and the expression of a specific miRNA in SLE patients compared to controls. The study suggests that studying the microbial profile of SLE patients could lead to more effective treatments based on the microbiota. [Extracted from the article]

A recent study conducted by the Mexican Social Security Institute examined the expression of Toll-like Receptor 7 (TLR7) and TLR9 in patients with recently diagnosed Class III and Class IV lupus nephritis (LN). The study found that there was a significant increase in the expression of TLR7 protein in Class III LN patients compared to healthy control subjects. Conversely, the expression of TLR9 showed a decrease in LN Class III patients. The study also observed improvements in certain renal function markers, such as complement C3 levels and anti-DNA antibodies, but inconsistent results in overall renal function. The researchers concluded that the decreased expression of TLR9 and increased expression of TLR7 could be useful in the early diagnosis of Class III and Class IV LN. [Extracted from the article]

A recent report from the University of Washington discusses research on lupus, a chronic autoimmune disease. The study focuses on the subcellular location of certain proteins in lupus granulocytes, specifically the L1 retrotransposon-encoded ORF1p, DNA: RNA heteroduplexes, and the DNA sensor ZBP1. The researchers found that these proteins are co-expressed and co-localized in a subset of lupus granulocytes, and their concentration in cytosolic dots may contribute to the targeting of these proteins by autoantibodies in the disease. This research provides new insights into the composition of ORF1p granules in lupus neutrophils. [Extracted from the article]

A recent study conducted by researchers from Monash University in Melbourne, Australia, explores the role of Lyn tyrosine kinase in immune cell signaling and its implications for systemic lupus erythematosus (SLE), a debilitating autoimmune disease. The study highlights the importance of Lyn in maintaining tolerance and the development of lupus-like disease in mice lacking Lyn or expressing a gain-of-function mutation. The researchers provide an overview of Lyn's targets and its function in B lymphocytes and myeloid cells, as well as an update on studies of Lyn in SLE patients. This research contributes to a better understanding of the complex mechanisms involved in SLE and may aid in the stratification of patients based on Lyn function. [Extracted from the article]

A new report discusses research findings on lupus, a chronic autoimmune disease. The study aimed to analyze global research on genetic mutations, antibodies, and cytokines involved in the development of lupus. The results revealed several genes associated with abnormal activation of B- and T-cells, as well as an increase in specific autoantibodies in active lupus. The researchers plan to further investigate the association of genes, antibodies, and cytokines in the local Kazakh population and develop a genetic-immunologic panel for early diagnosis. [Extracted from the article]

A study conducted in Guatemala aimed to understand the role of the HLA-DRB1 and HLA-DQB1 genes in the development of systemic lupus erythematosus (SLE), an autoimmune disorder. The study analyzed the allelic and haplotype profiles of these genes in 50 SLE patients and compared them to a control group of 127 healthy Guatemalan subjects. The results showed a potential protective effect of certain alleles and haplotypes, as well as a risk association with others. This research provides insights into the genetic factors involved in SLE development in the Guatemalan population. [Extracted from the article]

A recent report from Saint-Petersburg State Pediatric Medical University discusses the role of interferon I (IFN I) signaling hyperactivation in systemic lupus erythematosus (SLE), particularly in childhood-onset SLE (cSLE). The study evaluated the IFN-I score and SLE-associated genetic variants in 80 patients with cSLE. The researchers found that 77% of patients had elevated IFN-I scores, and more than half of the patients had rare genetic variants associated with SLE. The study suggests that the IFN-I score could be a useful tool for identifying patients who may benefit from further genetic assessment for monogenic lupus. [Extracted from the article]

A recent study conducted by researchers at the State University of New York (SUNY) Downstate Health Sciences University in Brooklyn has found that protein kinase C delta (PKCd) plays a crucial role in protecting against systemic lupus erythematosus (SLE), an autoimmune disease characterized by anti-double stranded (ds) DNA IgGs. The study revealed that PKCd acts as a key regulator of B cell tolerance by selectively deleting anti-dsDNA B cells in the germinal center (GC). The researchers suggest that targeting PKCd's tolerance activity in the GC could potentially be a therapeutic approach for inhibiting lupus autoimmunity. [Extracted from the article]

New research from the Instituto Nacional de Pediatria in Mexico explores the role of a specific genetic variation in the development of lupus nephritis (LN) in childhood-onset systemic lupus erythematosus (cSLE) patients. The study focuses on a DNA copy number variation (CNV) in the VANGL1 gene, which has been proposed as a genetic factor in LN development in adult systemic lupus erythematosus (SLE) patients of European descent. The research found that the CNV allele and heterozygous genotype had a significant protective effect against LN development in Mexican cSLE patients. The study highlights the genetic heterogeneity underlying susceptibility to LN. [Extracted from the article]

A recent study conducted by researchers at Capital Medical University has found that long noncoding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) may serve as a potential biomarker for childhood-onset systemic lupus erythematosus (cSLE). The study analyzed the expression of lncNEAT1_1 and lncNEAT1_2 in peripheral blood samples from children diagnosed with cSLE, children diagnosed with juvenile idiopathic arthritis (JIA), and healthy children. The results showed that the expression of both lncNEAT1_1 and lncNEAT1_2 was significantly higher in patients with cSLE compared to healthy controls and patients with JIA. The study suggests that lncNEAT1_2, in particular, may be a promising biomarker for cSLE, especially in cases with fever, renal involvement, and low C3 levels. [Extracted from the article]

A study conducted by researchers from the Bannari Amman Institute of Technology in Tamil Nadu, India, has proposed a novel approach for improving the identification of Systemic Lupus Erythematosus (SLE) using gene-based predictive modeling and stacked deep learning classifiers. By combining transcriptomic data with clinical features and laboratory results, the model achieved a high accuracy value of 0.996, outperforming traditional diagnostic methods. The study highlights the potential of deep learning methods and open repositories like the Gene Expression Omnibus (GEO) database in advancing the diagnosis and management of SLE, offering strong performance and potential for precision medicine. [Extracted from the article]

A recent study conducted at the Royal London Hospital examined the clinical characteristics of male lupus patients in a multi-ethnic lupus center in East London, UK. The study found that male lupus was more prevalent among Afro-Caribbeans, followed by Asians and Caucasians. The median age at SLE diagnosis was 28 years, and the majority of males had multiorgan involvement, including renal, cutaneous, hematological, musculoskeletal, cardiac, pulmonary, and neurologic. The study also found a high prevalence of dsDNA, ENA (anti-Ro), and APL antibodies in male lupus patients. [Extracted from the article]

A recent study conducted at Duke University Medical Center in Durham, North Carolina, has explored the interplay between antinuclear antibodies (ANAs) and nuclear molecules in the development of systemic lupus erythematosus (SLE). SLE is an autoimmune disease that primarily affects young women and causes various inflammatory symptoms. The production of ANAs, specifically antibodies to DNA (anti-DNA), is a hallmark of SLE and can lead to the formation of immune complexes that contribute to inflammation and organ damage. The study highlights the role of immunologically active DNA in promoting inflammation throughout the body. [Extracted from the article]